To amend the Federal Food, Drug, and Cosmetic Act to modernize the methods of authenticating controlled substances in the pharmaceutical distribution supply chain, and for other purposes.

Bill 119 HR 1060 aims to update the Federal Food, Drug, and Cosmetic Act in order to improve the way controlled substances are authenticated in the pharmaceutical distribution supply chain. The bill seeks to modernize the methods used to verify the authenticity of these substances, with the goal of enhancing safety and security within the supply chain.

The proposed legislation includes provisions that would require the use of advanced technologies, such as blockchain and other digital authentication methods, to track and verify the movement of controlled substances throughout the distribution process. By implementing these technologies, the bill aims to reduce the risk of counterfeit or fraudulent drugs entering the supply chain, ultimately protecting consumers from potentially harmful substances.

In addition to enhancing authentication methods, the bill also includes measures to improve communication and collaboration among stakeholders in the pharmaceutical industry. This includes requirements for increased transparency and information sharing between manufacturers, distributors, and regulators, in order to better monitor and control the distribution of controlled substances. Overall, Bill 119 HR 1060 seeks to modernize and strengthen the authentication processes for controlled substances in the pharmaceutical supply chain, with the ultimate goal of improving safety and security for consumers.